Medtronic Implant Could Point to the Future of Parkinson’s Treatment

Medtronic ($MDT) has developed a first-of-its-kind implant, pairing traditional deep-brain stimulation with sensing technology, and, after performing its first procedure, the company says the device has a chance to change the standard of care for neurological disorders.

A German Parkinson’s patient was the first to be treated with Medtronic’s Activa PC+S device, an implant that administers standard DBS therapy all while sensing and recording electrical activity in key areas of the brain, something impossible before now, the company said.

Researchers have long sought a closed-loop DBS device, one that could read brain signals and then administer stimulation to treat patient-specific needs. Activa PC+S is a milestone in the effort to create such a device, Medtronic said, giving investigators a first step toward a self-regulating brain stimulator.

Print Friendly, PDF & Email

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button